COVID-19 Pandemic (Coronavirus)
- Thread starter null
- Start date
No sympathy for the unvaccinated
null
...
R-1 variant. It managed to infect 1/4 of the residents in a nursing home in Eastern Kentucky. Most of the residents were vaccinated. 1 vaccinated resident died and 2 unvaccinated residents died. It's currently in 47 states with 2,200 people infected with it across the country. 10,000 worldwide. It infects the vaccinated by overpowering the antibodies by producing more of itself once it enters the body and evading the bodies response to its presence. But yeah, those of us who are vaccinated shouldn't worry about those of you who aren't and the variants being produced amongst you.
R.1, Lambda etc are being crowded out (for the time being at least) by the more infectious delta.
So you disregarding human life because of a shot? People have choices obviously people are aware of the risk of covid and still take a chance on it. You don't have to have sympathy but you can respect people's individual choice. There's alot of children out there that can't be vaccinated yet so what it's no sympathy for them?
4,568 New Breakthrough Cases in Mass., 23 More Deaths in Vaccinated People
There no different than you. Everyone is in fear mode unvaccinated are in fear of not knowing what the long term affects of the shot and Vaccinated people are in fear of catching it. This is all about divisivness and picking a side to futher create chaos amongst the people.
No..Money..Mo..Problems
it is what it is
I had a weird throbbing feeling in my arm today, kinda had me spooked to get my second shot
Anyone else have that feeling?
That's the most common side effect
First shot my arm hurt for a week
Second shot my arm hurt for 3 days
And that was it
people are disregarding human life by knowingly sending their covid-positive children to school, knowingly showing up to work whilst having covid, etc. most people are gonna feel some type of way at the thought of them or their loved ones being exposed to that type of recklessness.
Your loved one's can be removed from life at anytime. People weren't feeling this type of way when people would show up sick with the flu or bronchitisis potential life threatening sicknesses. Your only paying attention now because you now have to wear a mask and you had to stay isolated in the house for a year to rewire your brain in fear. I'm not trying to argue with you and I understand your perspective. This is someone who has had covid and my reality is I took a chance on my own immune system with my choice and still alive and others are alive as well. If you don't want to bet on that I respect people who want to take the vaccine.
null
...
emotional thinker accusing others of thinking emotionally
I'm not accusing anyone of anything since I understand why some people think the way the do. Your reality is your reality breh.
Pfizer. I had no side effects too. But I’ve been pretty sick this week so the vax not causing side effects in me is not saying much.
MEXICO CITY, Sept 24 (Reuters) - The COVID-19 vaccine by Pfizer-BioNTech (PFE.N) will be the only one used in Mexico for at-risk children aged 12-17, Mexico's deputy health minister said on Friday.
"We can only use the Pfizer-BioNTech vaccine because it is the only one that has already been scientifically proven to be safe and effective in girls, boys and adolescents from 12 to 17 years old," Deputy Health Minister Hugo Lopez-Gatell said at a regular news conference.
"It is not ruled out that other pharmaceutical companies in due course also present their analysis and demonstrate the vaccines can also be used in children and adolescents," he added
The government estimates it will give vaccines to between 750,000 and 1.5 million at-risk children initially.
Mexico has applied so far for 97.5 million vaccine doses, according to government data. About 43.2 million people are fully vaccinated among its population of 126 million.
Mexico to use only Pfizer COVID-19 vaccine on at-risk kids
Possibly related
Pfizer plays hardball in Covid-19 vaccine negotiations - STAT
Allegedly pfizer asked for an embassy buildings and military bases as a guarantee against the cost of any future legal cases from Latin American countries causing a 3 month delay in vaccine availability
"We can only use the Pfizer-BioNTech vaccine because it is the only one that has already been scientifically proven to be safe and effective in girls, boys and adolescents from 12 to 17 years old," Deputy Health Minister Hugo Lopez-Gatell said at a regular news conference.
"It is not ruled out that other pharmaceutical companies in due course also present their analysis and demonstrate the vaccines can also be used in children and adolescents," he added
The government estimates it will give vaccines to between 750,000 and 1.5 million at-risk children initially.
Mexico has applied so far for 97.5 million vaccine doses, according to government data. About 43.2 million people are fully vaccinated among its population of 126 million.
Mexico to use only Pfizer COVID-19 vaccine on at-risk kids
Possibly related
Pfizer plays hardball in Covid-19 vaccine negotiations - STAT
Allegedly pfizer asked for an embassy buildings and military bases as a guarantee against the cost of any future legal cases from Latin American countries causing a 3 month delay in vaccine availability
Last edited:
Big gap between Pfizer, Moderna vaccines seen for preventing COVID-19 hospitalizations
Big gap between Pfizer, Moderna vaccines seen for preventing COVID-19 hospitalizations
MELISSA HEALY AND AMINA KHAN
Los Angeles Times
SEP 18, 2021
2:43 PM
Maggie Fox
Two-dose version of Johnson & Johnson shot 94% effective against COVID-19, company study finds
The surprising findings came as a Food and Drug Administration advisory panel recommended against offering booster doses of the Pfizer vaccine to all Americans ages 16 and older. In a striking rebuke, 16 of 18 experts told the agency it had not mustered enough data to make a third shot the norm.
In lengthy briefings to the panel, representatives from Pfizer pointed to clinical trial results involving 306 mostly healthy participants to argue that a booster “restores” the 95% vaccine effectiveness rate seen earlier in the pandemic.
Company officials also touted evidence from Israel, which rolled out boosters after seeing a rise in hospitalizations among people who were fully vaccinated. Those hospitalizations dropped dramatically after third doses were given, Israeli scientists have said.
But panel members made clear that despite Pfizer’s aggressive stance, it had not gathered enough evidence that a third shot was safe for young people and for those at lesser risk of becoming severely ill with COVID-19.
“We need age-specific data” on the safety and protective benefits of a further booster, said Dr. Ofer Levy, a panel member who directs the Precision Vaccines program at Boston Children’s Hospital.
FDA clearance for booster shots for everyone 16 and older would be seen as something “close to a mandate,” said Dr. Eric Rubin, a panel member and infectious-disease expert at the Harvard T.H. Chan School of Public Health. Rubin worried that such a move could redefine what it takes to be considered fully vaccinated against COVID-19.
“None of us are there yet,” he said.
Carolyn Y. Johnson
Pfizer: Low dose of COVID-19 vaccine safe for 5- to 11-year-olds, shows 'robust' antibody response
But others apparently are. Dr. Anthony Fauci, President Joe Biden’s top adviser on vaccines, has come out strongly in favor of booster shots, saying before Friday’s vote that a failure to endorse the shots “would be a mistake.”
And in mid-August, Biden himself said his administration would begin making booster shots available the week of Sept. 20 to those vaccinated for at least eight months.
Biden cautioned at the time that his plan was contingent on FDA approval. But his announcement stoked concerns of political meddling in a matter that required the unhindered evaluation of scientists.
“This should demonstrate to the public that the members of this committee are independent of the FDA,” Dr. Archana Chatterjee, dean of the Chicago Medical School, said after the vote. “In fact, we do bring our voices to the table when we are asked to serve on this committee.”
The panel unanimously agreed that a third shot of the vaccine now sold under the brand name Comirnaty should be offered to select groups: individuals 65 and older, people at risk of developing severe disease, and those, including health-care workers, whose occupations put them at high risk of infection.
Dr. Peter Marks, who leads the FDA’s evaluation of drugs and vaccines, told panel members that the agency could give its blessing to booster shots with an emergency use authorization — a regulatory step that falls short of the full approval Pfizer had sought.
The company issued no statement Friday in response to the panel’s vote.
Researchers in the United States have been warning for months that the immunity afforded by COVID-19 vaccines might be waning. The CDC reported that in late July, close to three-quarters of the 469 people swept up in a Massachusetts outbreak were fully vaccinated. And the agency has launched several studies aimed at detecting changes in vaccine effectiveness in healthcare workers and others who were vaccinated early.
But virtually all of those infections appeared to be mild. And health officials eager to induce vaccine skeptics to step up for their shot — including Fauci and Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention — have repeatedly praised the vaccines for keeping most fully vaccinated people out of hospitals.
The new report on waning vaccine efficacy challenges that expectation.
Researchers from around the country found striking differences between two mRNA vaccines long thought to be interchangeable.
When the Moderna vaccine received emergency use authorization in December, the company reported that 30 people in its clinical trial developed severe cases of COVID-19, including nine who required hospitalization. All 30 patients were in the placebo group, resulting in a vaccine efficacy against severe disease of 100%.
Ten people in Pfizer’s initial clinical trial developed severe cases of COVID-19. Nine of them was in the placebo group, including seven who were hospitalized, resulting in a vaccine efficacy against severe disease of 88.9%.
Once the Moderna and Pfizer vaccines were rolled out to the public, their records of preventing COVID-19 hospitalizations in the first four months were neck and neck — 93% and 91% effective, respectively. But the degree of protection diverged after that.
When they focused specifically on the period 120 days beyond the second dose, the study authors found that the Moderna vaccine remained 92% effective at preventing COVID-19 hospitalizations. But the equivalent figure for the Pfizer vaccine was 77%.
The results were published in the CDC’s Morbidity and Mortality Weekly Report.
Both the Pfizer and Moderna vaccines are based on mRNA technology, which delivers temporary instructions to the body’s muscle cells that help it learn to recognize the spike protein, a key part of the coronavirus’ structure. But “they’re actually not necessarily interchangeable,” said Dr. Timothy Brewer, a professor of medicine and epidemiology at UCLA.
Each vaccine is formulated and administered differently, Brewer said, and those differences could affect the strength and duration of the two vaccines’ protection.
Moderna’s shot contains 100 micrograms of vaccine, more than three times the 30 micrograms in the Pfizer shot. And Pfizer’s two doses are given three weeks apart, while Moderna’s two-shot regimen is administered with a four-week gap.
Brewer also pointed to evidence that the Moderna vaccine seemed to elicit higher levels of a key antibody than the Pfizer vaccine.
“We know from other studies the neutralizing antibody levels will decay over time, so starting at a higher level will mean that you have farther to go before you decay to a point where efficacy drops off,” he said.
Dr. Robert Murphy, who directs Northwestern University’s Institute for Global Health, said the Pfizer vaccine’s reduced protection against severe disease may bolster the case for boosters for all who got the vaccine, not just the specific groups identified by the FDA advisory panel.
“Based on the data I have seen, persons who received the Pfizer vaccine would benefit from a booster dose at this time,” he said. “I don’t see why we have to wait until the younger people get sick and become hospitalized.”
But Dr. Arnold Monto, who chairs the FDA advisory panel, applauded the agency’s willingness to withhold a full-throated call for boosters until a stronger case can be made. And he suggested that as more evidence accumulates, boosters for all might still get the nod.
“That’s the beauty of the emergency use authorization,” said Monto, an epidemiologist at University of Michigan. “It can be changed based on changing data.”
First Published September 18, 2021, 2:43pm